에스토니아 - 에스토니아어 - Ravimiamet

mcneil healthcare (ireland) limited - ksülometasoliin+dekspantenool - ninasprei, lahus - 0,5mg+50mg 1ml 10ml 1tk

에스토니아 - 에스토니아어 - Ravimiamet

hospira uk limited - gemtsitabiin - infusioonilahuse kontsentraat - 38mg 1ml 52.6ml 1viaal; 38mg 1ml 5.3ml 1viaal; 38mg 1ml 26.3ml 1viaal

에스토니아 - 에스토니아어 - Ravimiamet

viatris healthcare limited - flutikasoon+aselastiin - ninasprei, suspensioon - 50mcg+137mcg 1mõõtannus 28annus 10tk; 50mcg+137mcg 1mõõtannus 120annus 1tk; 50mcg+137mcg 1mõõtannus 28annus 1tk

에스토니아 - 에스토니아어 - Ravimiamet

viatris healthcare limited - flurbiprofeen - suuõõnesprei, lahus - 2,5mg 1ml 15ml 1tk

에스토니아 - 에스토니아어 - Ravimiamet

viatris healthcare limited - flutikasoon+aselastiin - ninasprei, suspensioon - 50mcg+137mcg 1mõõtannus 28mõõtannus 1tk; 50mcg+137mcg 1mõõtannus 120mõõtannus 1tk; 50mcg+137mcg 1mõõtannus 28mõõtannus 10tk; 50mcg+137mcg 1mõõtannus 120mõõtannus 3tk

에스토니아 - 에스토니아어 - Ravimiamet

mcneil healthcare (ireland) limited - ksülometasoliin+dekspantenool - ninasprei, lahus - 1mg+50mg 1ml 10ml 1tk

에스토니아 - 에스토니아어 - Ravimiamet

viatris healthcare limited - flurbiprofeen - suuloputuslahus - 2,5mg 1ml 160ml 1tk

에스토니아 - 에스토니아어 - Ravimiamet

cipla (eu) limited - mometasoon - ninasprei, suspensioon - 50mcg 1annus 140annus 1tk

유럽 연합 - 에스토니아어 - EMA (European Medicines Agency)

plethora pharma solutions limited - lidokaiin, prilocaine - enneaegne ejakulatsioon - anesteetikumid - senstend on näidustatud ravi esmase enneaegne ejakulatsioon täiskasvanud mehed.

유럽 연합 - 에스토니아어 - EMA (European Medicines Agency)

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - suhkurtõbi, tüüp 2 - diabeetis kasutatavad ravimid - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. , kolmekordne kombineeritud ravi) lisandina toitumise ja treeningu patsientidel, ebapiisavalt kontrollitud nende maksimaalne talutav annus metformiin ja sulphonylurea. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.